MedImmune team up for immuno-oncology clinical trial Advaxis.
As multiple companies vie for a competitive benefit later on PD-L1 market, the power of our immunotherapy platform to assault multiple tumour targets helps it be an attractive combination therapy.?.. Advaxis, MedImmune team up for immuno-oncology clinical trial Advaxis, Inc. , a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a scientific trial collaboration with MedImmune, the global biologics study and development arm of AstraZeneca. Preclinical evidence suggests that the mix of ADXS-HPV with a checkpoint inhibitor, such as for example MEDI4736, can enhance overall anti-tumour response. Bahija Jallal, Executive Vice President, MedImmune. The Phase I section of the trial can be expected to set up a recommended dose program of MEDI4736 with ADXS-HPV, and the Stage II portion will measure the efficacy and security of the combination. (more…)